1. [Oncology-related issues of angiotensin-receptor blockers].
- Author
-
Telekes A and Kiss I
- Subjects
- Angiotensin II Type 1 Receptor Blockers therapeutic use, Angiotensin Receptor Antagonists administration & dosage, Angiotensin Receptor Antagonists adverse effects, Animals, Antihypertensive Agents administration & dosage, Antihypertensive Agents adverse effects, Antineoplastic Agents administration & dosage, Antineoplastic Agents therapeutic use, Diabetic Nephropathies drug therapy, Drug Approval, Drug Therapy, Combination, Heart Failure drug therapy, Heart Failure prevention & control, Humans, Hypertension drug therapy, Myocardial Infarction drug therapy, Neoplasms drug therapy, Renin-Angiotensin System drug effects, Stroke prevention & control, Angiotensin Receptor Antagonists therapeutic use, Antihypertensive Agents therapeutic use, Antineoplastic Agents pharmacology, Carcinogens pharmacology
- Abstract
Recently controversial data emerged regarding the cancer inducing activity of angiotensin-receptor blockers. There may be several reasons which may explain the controversial data published in the scientific literature including wrong trial design or misinterpretation of data. Considering the large number of patients receiving treatment for hypertension, it is essential to have a clear view of the cancer-related safety of these drugs. This paper tries to give an overview on this issue based on data available in the literature. According to our present knowledge, angiotensin-receptor blockers exert more likely anticancer activity rather than carcinogenesis inducing effect. In fact, some oncologic trials point to this direction, because angiotensin-receptor blockers are suggested as co-treatment to chemotherapy in cases of pancreatic, oesophageal and gastric cancers.
- Published
- 2015
- Full Text
- View/download PDF